Roche has launched the cobas MPX-E donor screening assay, a qualitative in-vitro diagnostic test for detecting and differentiating human immunodeficiency virus (HIV 1 and 2), as well as hepatitis B, C, and E.
The new assay is now available across countries that accept the CE mark, aiming to enhance blood safety by consolidating screening for these pathogens.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
It combines detection of the four viral targets into a single workflow, supporting laboratories in streamlining their processes.
The cobas MPX-E assay is developed to address the current demands of laboratories. It enhances sensitivity and specificity, particularly assisting in preventing the transmission of HEV through transfusions.
Additional features include dual-target detection for HIV-1 group M, targeting two separate regions of the viral genome. This approach helps improve sensitivity and increases reliability even if mutations occur within the viral genome.
The new assay operates on the cobas x800 systems (cobas 5800/6800/8800), already used globally for more than ten million tests monthly.
As a multiplex real-time PCR test, it enables simultaneous detection and differentiation of HIV, HBV, HCV, and HEV. Laboratories can select flexible testing options, screening all four pathogens or individual ones as needed.
For labs already screening for HEV, this assay shortens result turnaround; for others planning HEV implementation, cobas MPX-E delivers a cost-effective solution without additional space or hardware requirements.
Roche Diagnostics CEO Matt Sause said: “Safe, timely access to blood products is a cornerstone of modern healthcare.
“With the launch of the cobas MPX-E test, we will help ensure that patients receive the safe blood products they need by providing a fully integrated solution that includes the most critical viral pathogens and improves lab efficiency.”
Earlier this month, Roche conducted a new global survey of diabetic patients, which revealed that many participants wanted predictive tools to assist them in managing their condition.
